The U.S. Food and Drug Administration (FDA) has authorized the first over-the-counter continuous glucose monitoring (CGM) device designed for young children. The newly expanded approval allows the Stelo Glucose Biosensor System to be used by children aged two years and older who do not require insulin therapy.
This milestone represents a significant advancement in diabetes management and preventive health monitoring for families. Until now, continuous glucose monitoring technology was largely available through prescription channels or limited to specific patient groups. With this decision, parents and caregivers have access to a non-prescription tool that can help them better understand how daily habits influence a child's glucose levels.
The Stelo Glucose Biosensor System is a wearable glucose monitoring device developed by Dexcom. The system includes a small sensor that adheres to the skin and connects to a smartphone application. Once activated, the sensor measures glucose levels every 15 minutes and sends the information directly to the paired mobile device.
This continuous tracking provides users with valuable insights into glucose trends throughout the day and night. Instead of relying on occasional finger-prick tests, families can view ongoing patterns and gain a clearer understanding of how meals, physical activity, and lifestyle choices affect blood sugar levels.
Each sensor is designed to be worn for up to 15 days before replacement is required.
The FDA's decision is particularly important because it extends access to CGM technology beyond adults and prescription-only users. Stelo was initially approved for adults aged 18 and older in 2024. The latest clearance expands availability to children under 18, making it the first over-the-counter CGM approved for pediatric use.
Health experts have expressed growing concern about increasing rates of prediabetes and type 2 diabetes among children and adolescents. Early awareness of glucose patterns may help families make informed decisions about nutrition, exercise, and overall wellness.
The approval also reflects broader efforts to improve access to healthcare technology and empower consumers with actionable health data.
According to FDA guidance, the Stelo Glucose Biosensor System is intended for:
The system is designed to support health awareness and informed decision-making. However, it is not a substitute for professional medical care or clinical diagnosis.
Continuous glucose monitors use a small sensor placed just beneath the skin to measure glucose levels in the body's interstitial fluid. The sensor automatically collects readings at regular intervals and transmits the data to a connected application.
Unlike traditional glucose testing methods, CGMs provide a continuous stream of information rather than isolated measurements. This allows users to identify trends, recognize patterns, and understand how different activities impact glucose responses.
For parents, this technology may offer greater visibility into a child's health and provide useful information when discussing concerns with healthcare professionals.
Several features make the Stelo Glucose Biosensor System appealing for families and individuals seeking convenient glucose monitoring:
The device automatically records glucose readings every 15 minutes, helping users monitor fluctuations throughout the day.
Glucose data can be viewed directly through a compatible smartphone application, making information easily accessible.
Each sensor can be worn for up to 15 days, reducing the frequency of replacements.
According to the manufacturer, the biosensor can function underwater at depths of up to eight feet for as long as 24 hours when properly applied.
The over-the-counter status eliminates the need for a prescription, improving accessibility for many families.
The expanded approval may offer several advantages for parents and caregivers seeking greater insight into a child's health.
Continuous monitoring can help families understand how different foods, activities, and routines influence glucose levels.
Real-time data may encourage healthier eating habits, increased physical activity, and more informed wellness choices.
For children with diabetes who do not use insulin, the system can serve as an additional tool for monitoring glucose trends and supporting treatment plans.
The data generated by the device can help children and caregivers learn about the relationship between nutrition, exercise, and metabolic health.
Although the device offers many potential benefits, it is not suitable for everyone.
The FDA has specifically stated that the Stelo Glucose Biosensor System is not intended for:
One important limitation is that the device does not provide alerts for dangerously low blood sugar levels. Because of this, individuals who require immediate warnings about hypoglycemia should use alternative monitoring systems recommended by their healthcare providers.
The FDA also advises individuals with a history of eating disorders to consult a medical professional before using glucose monitoring technology. In some cases, excessive focus on glucose data may not be beneficial and could potentially contribute to unhealthy behaviors.
Clinical evaluations of the device identified several generally mild adverse events. Some users experienced:
Parents should monitor the sensor area regularly and follow all manufacturer instructions regarding placement, cleaning, and replacement.
If irritation, swelling, or signs of infection develop, medical advice should be sought promptly.
The FDA's approval of the first over-the-counter CGM for young children reflects a growing trend toward consumer-friendly health technology. Wearable devices continue to transform how people track and manage their health, providing real-time information that was once available only in clinical settings.
As diabetes and metabolic health concerns continue to affect younger populations, tools like the Stelo Glucose Biosensor System may play an increasing role in prevention, education, and early intervention.
While these devices should never replace professional medical care, they can provide families with valuable insights that support healthier lifestyle choices and more informed conversations with healthcare providers.
The FDA's clearance of the Stelo Glucose Biosensor System for children aged two and older marks a significant development in pediatric glucose monitoring. As the first over-the-counter CGM approved for use in children, the device expands access to continuous glucose tracking and provides families with a new way to understand how daily habits affect blood sugar levels.
With smartphone connectivity, extended wear capability, and non-prescription availability, the system offers convenience and accessibility. However, users should remain aware of its limitations and consult healthcare professionals before making medical decisions based on the device's data.
This article is intended for informational and educational purposes only and should not be considered medical advice, diagnosis, or treatment. The information presented summarizes publicly available reports and regulatory announcements. Individual health needs vary significantly, and readers should consult a qualified healthcare professional before making decisions regarding medical care, glucose monitoring, medications, or lifestyle changes. The use of any medical device should follow manufacturer instructions and healthcare provider recommendations.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.